Drug Trial Radar · NCT05869955
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Sep 13, 2023
Primary completion
Aug 29, 2028
Study completion Aug 29, 2028
Sponsor
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb Services Unlimited Company
- First posted
- May 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
Conditions
- Systemic Lupus Erythematosus
- Idiopathic Inflammatory Myopathy
- Systemic Sclerosis
- Rheumatoid Arthritis
Interventions
CC-97540Drug
Specified dose on specified days
FludarabineDrug
Specified dose on specified days
CyclophosphamideDrug
Specified dose on specified days
TocilizumabDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (AEs) in each indication.Time frame: Up to 2 years after CC-97540 infusion
- Number of participants with serious AEs (SAEs) in each indication.Time frame: Up to 2 years after CC-97540 infusion
- Number of participants with AEs of special interest (AESI) in each indication.Time frame: Up to 2 years after CC-97540 infusion
- Number of participants with laboratory abnormalities in each indication.Time frame: Up to 2 years after CC-97540 infusion
- Number of participants with Dose Limiting Toxicities (DLT) in each indication.Time frame: Up to 2 years after CC-97540 infusion
- Recommended Phase 2 Dose (RP2D) of CC-97540 in each indication.Time frame: Up to 2 years after CC-97540 infusion
Locations
46 sites in 6 countries. Site status is shown where the registry gives one.
Local Institution - 0035
Aurora, Colorado
Local Institution - 0024
Denver, Colorado
Local Institution - 0006
Jacksonville, Florida
Local Institution - 0056
Miami, Florida
Local Institution - 0053
Chicago, Illinois
Local Institution - 0038
Boston, Massachusetts
Local Institution - 0033
Worcester, Massachusetts
University of Massachusetts Chan Medical School
Worcester, Massachusetts
Local Institution - 0031
Ann Arbor, Michigan
Local Institution - 0037
Detroit, Michigan
Local Institution - 0022
Rochester, Minnesota
Local Institution - 0010
St Louis, Missouri
Local Institution - 0028
Omaha, Nebraska
Local Institution - 0008
Summit, New Jersey
Local Institution - 0002
New York, New York
Local Institution - 0011
New York, New York
Local Institution - 0007
New York, New York
Local Institution - 0003
Chapel Hill, North Carolina
Local Institution - 0005
Cleveland, Ohio
Local Institution - 0036
Dallas, Texas
Local Institution - 0029
Houston, Texas
Local Institution - 0034
Houston, Texas
Local Institution - 0004
Seattle, Washington
Local Institution - 0057
Seattle, Washington
Local Institution - 0058
Seattle, Washington
Local Institution - 0019
Leuven, Vlaams-Brabant, Belgium
Local Institution - 0016
Lille, France
Local Institution - 0040
Nice, France
Local Institution - 0018
Paris, France
Local Institution - 0020
Rennes, France
Local Institution - 0044
Pessac, Aquitaine, France
Local Institution - 0015
Montpellier, Hérault, France
Local Institution - 0025
Berlin, Germany
Local Institution - 0047
Düsseldorf, Germany
Local Institution - 0017
Erlangen, Germany
Local Institution - 0049
Würzburg, Bavaria, Germany
Local Institution - 0042
Cologne, North Rhine-Westphalia, Germany
Local Institution - 0041
Leipzig, Saxony, Germany
Local Institution - 0045
Magdeburg, Saxony-Anhalt, Germany
Local Institution - 0012
Rome, Lazio, Italy
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.